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The optimal timing of hematopoietic cell transplantation
(HCT) in AML is still under debate. We addressed this ques-
tion in the AML 2003 study, a large, multicenter, open-label,
randomized study of the German SAL group. All patients
received one cycle of induction therapy (IT). Upfront
molecular characterization, HLA typing and donor search
were performed. The transplant strategy was tailored to AML
risk and to donor availability. Patients aged 18-60 years were
randomly assigned upfront 1:1 to either one of two trans-
plant strategies: In the control arm HLA-identical sibling HCT
was scheduled in ﬁrst complete remission for patients with
intermediate cytogenetic risk AML and related or unrelated
compatible HCT for patients with a complex karyotype (CK).
In the experimental arm the indication for allogeneic HCT
was extended to patients with an FLT3-ITD allelic ratio >0.8
(mutant/wild type), >10% marrow blasts on day 15 after IT1
and patients with adverse karyotypes, including: -7, -5,
del(5q), inv(3q), t(3;3), t(6;9), t(6;11), t(11;19) (q23;p13.1).
Furthermore, HCT was scheduled earlier, i.e. in aplasia after
the ﬁrst or the second cycle of IT.
Between December 1st, 2003 and November 26th, 2009
1179 patients were assigned randomly either to the experi-
mental (N¼598) or the control intervention (N¼581). The
median age was 48 years (range, 18 to 60 years) and the
median observation time now is 52 months. In the intent-to-
treat analysis the hazard ratio of the treatment effect
(experimental versus control) was 0.92 (95% CI, 0.75 to 1.14;
P ¼ .45) for the primary endpoint overall survival (OS) and
0.85 (95% CI, 0.71 to 1.02; P¼ .08) for the secondary endpoint
event-free survival (EFS). However, the rate of patients who
received allogeneic HCT as ﬁrst post-remission therapy was
only 39% in the experimental arm and 20% in the control arm.
Thus, the analysis according to the intent-to-treat could not
discriminate appropriately between the two treatment
strategies. In an exploratory analysis, we therefore analyzed
the effect of allogeneic HCT as a time-dependent covariate in
a Cox-regressionmodel. We adjusted for the cytogenetic risk,age, ECOG performance status, white blood cell count, and
LDH at diagnosis. In this as-treated analysis the adjusted
hazard ratio for the treatment (allogeneic HCT versus
chemotherapy) was 0.73 (95% CI, 0.59 - 0.89; P ¼ .002) for OS
and 0.67 (95% CI, 0.55 - 0.82; P < .001) for EFS. This analysis
corrects appropriately for a classical time-selections bias.
However, a patient selection based on comorbidity or ﬁtness
cannot be ruled out.
In conclusion, a survival beneﬁt from early compared to
late allogeneic HCT could not be shown in the intent-to-treat
analysis of this large randomized trial using a risk-adapted
transplant strategy. However, the results of the as-treated
analysis suggest a substantial beneﬁt from allogeneic HCT in
ﬁrst remission versus chemotherapy.
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Mixed phenotype acute leukemia (MPAL) is a rare
leukemia with features of both myeloid and lymphoid
lineage. The 2008 World Health Organization (WHO) deﬁ-
nition of MPAL is based on the expression of strictly speciﬁc
T-lymphoid (cytoplasmic CD3) and myeloid (myeloperox-
idase) antigens, and B-cell lineage assignment relies on the
expression of CD19 together with other B celleassociated
markers (Borowitz et al. World Health Organization Classi-
ﬁcation of Tumours: Pathology and Genetics of Tumours of
Haematopoietic and Lymphoid Tissues. 2008). In this retro-
spective review, we analyzed the clinical features and
treatment outcomes of patients treated at MDACC between
5/2004 and 6/2012 who fulﬁlled the diagnostic criteria for
MPAL. We identiﬁed a total of 41 patients with a median age
of 47 years (range 9 e 82; 63% male) with characteristics
described in the table below. Twenty one (51%) patients had
leukemia with myeloid plus B-lymphoid (M/B) markers, 18
(44%) with myeloid plus T-lymphoid (M/T) markers, and 2
(5%) with B-lymphoid plus T-lymphoid (B/T) markers. Cyto-
genetic analysis showed 31 patients (76%) had an abnormal
